Clinical trials: Human Brain and Cognition
Stress
CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?
This clinical trial will investigate whether a powdered prebiotic fibre blend can improve perceived stress levels in healthy adults with mild-severe stress levels.
- Trial name
- CALM (NCT07201909)
- Testing
- Prebiotic fibre blend, Maltodextrin powder
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Myota GmbH
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969136
- Testing
- Drug: EVP-6124
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 403 people
- Sponsor
- FORUM Pharmaceuticals Inc
Brain Concussion, Mild Cognitive Impairment
Development of a Neurocognitive Screening Test
This research study will evaluate a standalone software application and is designed to standardize and validate new neurocognitive screening testing for children aged 6 through 11, and adolescents and adults ages 12 through 75.
- Trial name
- NCT02597504
- Testing
- Pen and paper neuropsychological test, Quick Test
- Where
- 4 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- ImPACT Applications, Inc.
Lennox-Gastaut Syndrome
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).
- Trial name
- EPI-COG (NCT04133480)
- Testing
- GWP42003-P
- Sponsor
- Jazz Pharmaceuticals
Alzheimer's Disease
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.
- Trial name
- NCT01066546
- Testing
- Dimebon tablet for oral administration
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Engagement, Patient, Quality of Life
SimpleC Wellness Platform With Social Robot Interaction (Long-term)
This study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Quality of Life, Mood, Aging Well
- Trial name
- NCT05599503
- Testing
- Behavioral Interventions, Robot Interventions
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- SimpleC, LLC
Alzheimer's Disease, Mild Cognitive Impairment
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
This study will evaluate the safety, tolerability, and pharmacokinetics of MK-4334 administered once daily (QD) in participants with Alzheimer's clinical syndrome receiving a stable, daily dose of donepezil 10 mg, taken orally…
- Trial name
- NCT03740178
- Testing
- MK-4334, Donepepzil
- Sponsor
- Merck Sharp & Dohme LLC
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
Neuropsychiatric systemic lupus erythematosus with cognitive impairment (NPSLE-CI) is a serious, disabling, and potentially life-threatening manifestation of SLE, affecting up to 80% of patients with cognitive impairments ("brain…
- Conditions
- Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
- Trial name
- NCT07281105
- Testing
- EG-501
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Evergreen Therapeutics, Inc.
Stress
BALANCE Study: Beneficial Effects of A Diverse Prebiotic Fibre bLend on Affect, iNflammation, Cognition, and the Gut microbiomE
This clinical trial will investigate whether a powdered prebiotic fibre blend, at two doses, can improve perceived stress levels in healthy adults with mild-severe stress levels.
- Trial name
- BALANCE (NCT07477470)
- Testing
- Prebiotic fibre blend
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myota GmbH
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Dementia, Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
- Trial name
- NCT00216593
- Testing
- galantamine hydrobromide
- Volunteers
- 415 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5)…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- FUTURE-US (NCT04951284)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Mild Cognitive Impairment, Dementia
An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.
GSK239512 is being developed for the treatment of symptoms of cognitive impairment in many diseases. GSK239512 is a drug that binds to the Histamine 3 receptor (a protein) in the brain (receptor occupancy).
- Trial name
- NCT00474513
- Testing
- GSK239512
- Where
- Canada
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults
This study is a multi-site, double-blind, randomized, controlled clinical trial to assess the safety and effectiveness of plasticity-based, adaptive, computerized-based cognitive remediation treatment versus a computer-based…
- Trial name
- e-CAeSAR (NCT01422902)
- Testing
- Plasticity-based Cognitive Training, Non-plasticity-based Training
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Posit Science Corporation
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Niemann-Pick Disease, Type C
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Due to different study designs, the sponsor separated Part C into this separate registration (NCT04958642), leaving Parts A/B in NCT02534844.
- Trial name
- NCT04958642
- Testing
- Adrabetadex
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 66 people
- Sponsor
- Mandos LLC